MedTrace Logo

Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

NCT01082393 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-12-08

No results posted yet for this study

Summary

We will investigate the process of vitiligo induction and the influence of different commonly used cream treatments on this process. Studies comparing different treatments for vitiligo in the induction stage of the disease are still missing. The study hypothesis = cream treatment can stop actively spreading vitiligo lesions during the early induction stage of the disease.

Conditions

  • Vitiligo

Interventions

DRUG

topical tacrolimus treatment

4 applications (day 1,day 3, day 6 and day10)

DRUG

topical pimecrolimus treatment

4 applications (day 1, day 3, day 6 and day 10)

DRUG

local mometasone furoate treatment

4 applications (day 1, day 3, day 6 and day 10)

DRUG

cold cream

4 applications (day 1, day 3, day 6 and day 10)

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Nanny Van Geel, MD, PhD · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-16
Primary Completion
2015-09-15
Completion
2015-12-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082393 on ClinicalTrials.gov